Caris Life Sciences Options were exercised for 400,000 shares at $2.44 each, while a separate transaction sold 400,000 shares at $30.33 each on 2026-09-17. For investors tracking CAI ownership, the records show 630,303 shares after the exercise and 230,303 after the sale.
Key Highlights
- Brille Brian J held 1,600,000 derivative securities after exercising options for 400,000.
- The separate share sale was priced at $30.33 per share.
- The option exercise represented about 20.0% of the prior derivative securities holding.
Caris Life Sciences, Inc. (NASDAQ: CAI) is a biotechnology company. Brille Brian J exercised options for 400,000 shares at $2.44 per share on 17 September 2026, alongside a separate sale of 400,000 shares at $30.33 per share.
Option Exercise and Share Sale Details
The M transaction code identifies an option exercise involving Caris Life Sciences shares. After that transaction, Brille Brian J held 630,303 shares, with the exercise representing about 63.5% of the resulting share holding. The separate S-coded transaction sold 400,000 shares at $30.33 per share and left Brille Brian J with 230,303 shares, equal to about 63.5% of the prior share holding.
Derivative Securities Position
The option exercise also covered 400,000 derivative securities. Brille Brian J held 1,600,000 derivative securities after the transaction. The exercised amount represented about 20.0% of the prior derivative securities holding.
FAQs
Q: How many Caris Life Sciences shares did Brille Brian J own after exercising the options?
A: Brille Brian J held 630,303 Caris Life Sciences shares after the option exercise. The exercise covered 400,000 shares priced at $2.44 each.
Q: What was the price of the Caris Life Sciences share sale?
A: The separate Caris Life Sciences share sale was conducted at $30.33 per share. It involved 400,000 shares on 17 September 2026.
Q: How many derivative securities did Brille Brian J hold after the exercise?
A: Brille Brian J held 1,600,000 derivative securities after exercising options for 400,000. The exercised amount represented about 20.0% of the prior derivative securities holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.